Treatment-resistant depression patients with baseline suicidal ideation required more treatments to achieve therapeutic response with ketamine/esketamine
Journal of Affective Disorders · 2024
DOI: 10.1016/j.jad.2024.01.262 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Affective Disorders, 2024. Verfasst von Balwinder Singh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, United States of America. Electronic address: singh.balwinder@mayo.edu. Hauptthemen laut MEDLINE: Ketamine, Major Depressive Disorder, Depressive Disorder, Treatment-Resistant. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Themen: Depression
Abstract (Originalsprache)
BACKGROUND: There is an urgent need to identify interventions to reduce suicidality. We investigated the antisuicidal effects of intravenous (IV) ketamine and intranasal (IN) esketamine among patients with treatment-resistant depression (TRD) in a historical cohort study. METHODS: The Quick Inventory of Depressive Symptomatology self-report (QIDS-SR) question 12 was used to measure suicidal ideation (SI). Cox proportional hazards models were used to evaluate associations between the number of treatments to response and baseline SI (yes, Q12 > 0 versus no, Q12 = 0), adjusting for covariates and modified baseline QIDS-SR score. We evaluated associations between the number of treatments to a 50 % reduction in SI score between IV and IN treatment. RESULTS: Fifty-two adults (62.5 % female, median age 49.1 years) received IV ketamine (71 %, n = 37) or IN esketamine (29 %, n = 15). Eighty-one percent of patients reported SI at baseline. Among those with baseline SI, 60 % had improved SI scores while 38 % did not change, and among those with no SI, 80 % did not change. After adjusting for covariates, the hazard ratios (HR) of response were significantly lower among those with baseline SI (HR = 0.36, 95 % CI, 0.14-0.92, p = 0.03). The number of treatments to achieve a 50 % reduction in SI score did not depend on group (IN esketamine vs. IV ketamine HR = 0.74 [95 % CI, 0.27-2.05]; p = 0.57). LIMITATIONS: Small sample size and lack of a placebo group. CONCLUSIONS: This study suggests that patients with baseline suicidal ideation require more treatments to achieve a response with ketamine or esketamine. The antisuicidal response seemed similar between IV ketamine and IN esketamine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, United States of America. Electronic address: singh.balwinder@mayo.edu.
- Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, United States of America.
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, United States of America.
Zitieren
APA
Singh, B., Vande Voort, J. L., Pazdernik, V. K., Frye, M. A., & Kung, S. (2024). Treatment-resistant depression patients with baseline suicidal ideation required more treatments to achieve therapeutic response with ketamine/esketamine. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2024.01.262
Vancouver
Singh B, Vande Voort JL, Pazdernik VK, Frye MA, Kung S. Treatment-resistant depression patients with baseline suicidal ideation required more treatments to achieve therapeutic response with ketamine/esketamine. Journal of Affective Disorders. 2024. doi:10.1016/j.jad.2024.01.262
BibTeX
@article{Singh2024,
author = {Singh, Balwinder and Vande Voort, Jennifer L and Pazdernik, Vanessa K and Frye, Mark A and Kung, Simon},
title = {Treatment-resistant depression patients with baseline suicidal ideation required more treatments to achieve therapeutic response with ketamine/esketamine},
journal = {Journal of Affective Disorders},
year = {2024},
doi = {10.1016/j.jad.2024.01.262}
}
EUVIMED